Answers are grounded in this paper and cite their sources.
Evaluation of: Spearman P, Lally MA, Elizaga M et al. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies, but limited breadth of neutralization in human volunteers. J. Infect. Dis. 203, 1165–1173 (2011).Designing an HIV-1 envelope glycoprotein (Env) that can induce broadly neutralizing antibodies in humans remains one of the great challenges in biomedical research. Monomeric gp120 has repeatedly failed to induce cross-neutralizing antibodies in clinical trials. Spearman et al. vaccinated uninfected volunteers with a trimeric gp140 protein. They found that the vaccine was safe and induced neutralizing antibody responses against the homologous virus, but not cross-neutralizing responses. The results reinforce the notion that our Env vaccine design needs to improve.
No takes yet. Share an insight, caveat, or question.
Rogier W. Sanders (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: